Everads Injector in suprachoroidal administration of an approved TA suspension for the treatment of patients with Diabetic Macular Edema: An open label safety and performance pilot study. - Nil

Everads Therapy Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1. Males and females more than or equal to 18 years of age with a diagnosis of type 1 or type 2 diabetes mellitus. 2. DME with central involvement at the screening visit, of more than or equal to 320 for males or more than or equal to 305 for females on Spectralis (Heidelberg), or more than or equal to 305 for males or more than or equal to 290 for females with Cirrus (Zeiss) by spectral domain optical coherence tomography (SD-OCT). 3. ETDRS BCVA letter score of less than 6/30 in the study eye for both the cohorts, with second eye BCVA of 6/21 or better in both the cohorts. 4.If both the eyes are eligible, the worse eye should be included in the trial and the other eye should receive standard care. If both eyes are eligible and have identical VA, the right eye needs to be included in the study. The untreated eye should receive the standard care by the PI post study treatment and follow up duration. 5.Have shown no response to three previous IVT treatment with antivascular endothelial growth factor (VEGF) agents. 6.Understands the language of the informed consent; willing and able to provide written informed consent prior to any study procedures; willing to comply with the instructions and attend all scheduled study visits. 7.For women at childbearing age: agreement to remain abstinent or use acceptable contraceptive methods.

•1.Evidence of macular edema due to any cause other than Diabetic retinopathy in the study eye. 2.Prior treatment with pan retinal photocoagulation or focal laser photocoagulation in the study eye within 90 days of screening visit. 3.Intraocular pressure more than or equal to 21 mmHg or uncontrolled glaucoma (open angle or angle closure) in the study eye. 4.History of any prior ophthalmic surgeries in the study eye within 90 days of the screening visit. 5.Patients for whom enrollment into the study, in the principal investigator’s opinion, would put the eye at undue risk for vision loss. 6.Previous treatment for DME with any intravitreal injection in the study eye in the last 90 days prior to the screening visit. 7.Any previous treatment with Ozurdex® implant in past 6 months. 8.Any previous treatment with Iluvien®. 9.Currently enrolled in an investigational drug or device study or has used an investigational drug or device within 30 days or the Screening visit. 10.Any other pre-existing eye conditions or surgical complications that would interfere with the interpretation of study endpoints. 11.Current iris neovascularization, vitreous hemorrhage, tractional retinal detachment or epiretinal membrane involving the macula in the study eye. 12.Known hypersensitivity to any component of or to used suspension or topical anesthetic. 13.Known allergy to nickel. 14.Uncontrolled blood pressure. 15.Pregnant or lactating women.

发起方